Pharmafile Logo
Pharmafocus logo
Advanced Search

Kidney cancer

Showing 15 posts of 31 posts found.

FDA building

FDA approves AVEO’s kidney cancer treatment

March 11, 2021
Aveo, FDA, Kidney cancer, fotivda, rcc

The FDA has approved AVEO Oncology’s FOTIVDA drug for the treatment of adults with relapsed or refractory advanced renal cell …

News
merck-keytruda

Keytruda rejected for NHS use for bladder cancer, will be removed from the Cancer Drugs Fund

March 12, 2020
Sales and Marketing Cancer, Kidney cancer, MSD, NHS, NICE, blader cancer, keytruda, pharma

MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has been knocked back by NICE for use on the NHS as a treatment for …

News
eisa0008_web

Eisai releases new Phase 2 data for levatinib+everolimus combo in advanced kidney cancer

February 17, 2020
Research and Development, Sales and Marketing Cancer, Eisai, Kidney cancer, Lenvima, pharma, renal cell carcinoma

New Phase 2 data has been revealed for Eisai’s Lenvima (levatinib), delivered alongside Novartis’ everolimus, for the treatment of unresectable …

News
190509-f-jf989-059

NICE does not recommend cancer drug combination to the NHS

February 13, 2020
Business Services Cancer, Kidney cancer, NHS, NICE, keytruda, kidney disease

NICE has published draft guidance that does not recommend a new drug combination to combat untreated advanced renal cell carcinoma …

News
credit_-_daniel_leal-olivas-afp

Bavencio+Inlyta combo OK’d in Europe for first-line advanced kidney cancer

October 29, 2019
Manufacturing and Production, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma

Merck KGaA and Pfizer’s joint drug Bavencio (avelumab) has received European approval in combination with Inlyta (axitinib) in the first-line …

News

BMS Opdivo/Yervoy recommended for untreated kidney cancer via Cancer Drugs Fund

April 5, 2019
Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, Kidney cancer, NICE, UK, Yervoy, opdivo

NICE has revealed it is recommending that Bristol-Myers Squibb’s Opdivo (nivolumab), in combination with Yervoy (ipilimumab), be made available to …

News
shutterstock_38078521

Bavencio+Inlyta combo boosts progression-free survival in advanced kidney cancer

February 18, 2019
Research and Development, Sales and Marketing Bavencio, Cancer, Kidney cancer, Merck KGaA, Pfizer, inlyta, pharma

New interim data for the combination of Pfizer’s Bavencio (avelumab) and Merck KGaA’s Inlyta (axitinib) have been released, showing that …

News

Half of kidney cancer patients initially misdiagnosed

October 30, 2018
Manufacturing and Production Cancer, Kidney cancer, NHS, UK, diagnosis

Half of kidney cancer patients are initially misdiagnosed, according to data from Kidney Cancer UK’s patient survey. Despite being the …

News
merckincweb

MSD’s Keytruda with Pfizer’s Inlyta beats Sutent in most common kidney cancer

October 19, 2018
Medical Communications, Research and Development Cancer, Kidney cancer, MSD, Pfizer, inlyta, keytruda, pharma

MSD has unveiled new Phase 3 data on its blockbuster anti-PD-1 cancer therapy Keytruda (pembrolizumab) as part of a combination, …

News
shutterstock_159488225

Merck KGaA and Pfizer’s combo impresses in first-line treatment of advanced kidney cancer

September 12, 2018
Research and Development, Sales and Marketing Cancer, Kidney cancer, Merck KGaA, Pfizer, pharma

Bavencio (avelumab), Merck KGaA and Pfizer’s human anti-programmed death ligand-1 (PD-L1) antibody, combined with the latter’s Inlyta (axitinib) has shown …

News
180405-evolution-of-kidney-cancer

Evolutionary path of kidney cancer tracked, “born to be bad” type discovered

April 13, 2018
Medical Communications, Research and Development Kidney cancer, biotech, drugs, pharma, pharmaceutical

A massive effort funded by Cancer Research UK has been able to track the different evolutionary pathways of kidney cancer …

News
pfizer_hq_dark

Pfizer shuts down kidney cancer drug trial due to “futility”

April 11, 2018
Research and Development Cancer, Kidney cancer, Pfizer, inlyta, pharma

Pfizer has revealed that it has shut down a trial of its vascular endothelial growth factor (VEGF) inhibitor Inlyta (axitinib) …

News
shutterstock_273326141

Eisai and MSD team up to combine Lenvima and Keytruda in cancer

March 8, 2018
Sales and Marketing Cancer, Eisai, Kidney cancer, Lenvima, MSD, Merck, keytruda, pharma

Pharma heavyweights MSD (Merck) and Eisai have announced they are to join forces to develop and commercialise the latter’s tyrosine …

News
pfizer-building-logo1web

FDA expands use of Pfizer’s Sutent in kidney cancer

November 17, 2017
Medical Communications, Sales and Marketing Cancer, Kidney cancer, Pfizer, Sutent, pharma

Pfizer has announced that the FDA has expanded the use of its tyrosine kinase inhibitor Sutent (sunitinib malate) to include …

News
opdivo_1_1

BMS left red-faced as Opdivo+Yervoy fails to beat rival Pfizer drug in kidney cancer

August 16, 2017
Research and Development BMS, Kidney cancer, Yervoy, life sciences, opdivo, pharma, pharmaceutical

Bristol-Myers Squibb has been left somewhat red-faced after its combination of Opdivo (nivolumab) and Yervoy (ipilimumab) failed to show any …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024